Skip to main content

Table 1 Demographic and clinical characteristics of patients with Acinetobacter baumannii bacteremic pneumonia stratified by 14-day mortality

From: Influence of severity of infection on the effect of appropriate antimicrobial therapy for Acinetobacter baumannii bacteremic pneumonia

Characteristics

Survivors (n = 177)

Non-survivors (n = 159)

P-value

Demographics

 Male, No. (%)

128 (72.3)

122 (76.7)

.36

 Age, median (IQR), years

70 (67–72)

69 (66–72)

.64

 Acquired in ICU, No. (%)

91 (51.4)

90 (56.6)

.34

 Previous ICU admission

127 (71.8)

110 (69.2)

.61

 Length of hospitalization before bacteremia, median (IQR), days

36 (24–48)

35 (27–44)

.98

Comorbidities, No. (%)

 Charlson co-morbidity score

3.8 (3.4–4.2)

3.9 (3.5–4.2)

.75

  Malignancy

50 (28.3)

44 (27.7)

.91

  Solid tumor

42 (23.7)

30 (18.9)

.28

  Hematologic malignancy

8 (4.5)

21 (13.2)

.005

 Type 2 diabetes mellitus

63 (35.6)

44 (27.7)

.12

 Cerebrovascular accident

47 (26.6)

21 (13.2)

.002

 Hypertension

85 (48.0)

65 (40.9)

.19

 Immunosuppressant use

35 (19.8)

56 (35.2)

.001

 Liver cirrhosis

19 (10.7)

14 (8.8)

.55

 Chronic kidney disease

58 (32.8)

62 (39.0)

.23

 Coronary artery disease

29 (16.4)

24 (15.1)

.75

 Congestive heart failure

34 (19.2)

34 (21.4)

.62

 Chronic obstructive pulmonary disease

39 (22.0)

33 (20.8)

.78

 Collagen vascular disease

10 (5.7)

18 (11.3)

.06

 Chemotherapy

13 (7.3)

21 (13.2)

.08

 Neutropenia

8 (4.5)

13 (8.2)

.17

 Recent surgery

64 (36.2)

32 (20.1)

.001

Invasive procedures, No. (%)a

 Arterial line

63 (35.6)

69 (43.4)

.14

 Central venous catheter

111 (62.7)

113 (71.1)

.11

 Hemodialysis

21 (11.9)

26 (16.4)

024

 Tracheostomy

44 (24.9)

50 (31.5)

.18

 Ventilator (previous use)

73 (41.2)

92 (57.9)

.002

 Ventilator (current use)

121 (68.4)

121 (76.1)

.12

 Ventilator associated pneumonia

121 (68.4)

113 (71.1)

.59

Clinical condition

 APACHE II score within 24 h before bacteremia, median (IQR)

23 (21–24)

33 (32–35)

<.001

 Shock

75 (42.4)

75 (47.2)

.38

Resistance profiles of bloodstream isolates, No. (%)

 Multidrug resistance (MDR)b

156 (88.1)

150 (94.3)

.046

 Carbapenem resistance

104 (58.8)

129 (81.1)

<.001

 Extensive drug resistance (XDR)c

58 (32.8)

95 (59.8)

<.001

Appropriate antimicrobial therapy

94 (53.1)

57 (35.9)

.001

  1. Abbreviations: APACHE II Acute Physiology and Chronic Health Evaluation II, ICU intensive care unit, IQR interquartile range
  2. aAt the time the blood culture was obtained
  3. bResistance to at least one agent in at least three of the following classes of antimicrobials: antipseudomonal cephalosporins, antipseudomonal carbapenems, ampicillin-sulbactam, fluoroquinolones, and aminoglycosides
  4. cExtensive drug resistance (XDR) referred to non-susceptibility to imipenem or meropenem and all drug class except for colistin and tigecycline